<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-0MTXXNR4/946ccfe1-7093-4547-8fb0-844ed46ebfc5/HTML"><dcterms:extent>20 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-0MTXXNR4/88ea85cc-bc5c-49a4-9afc-6358594e95e2/PDF"><dcterms:extent>515 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-0MTXXNR4/1a83483f-6404-4e52-aa4e-2985deb1a846/TEXT"><dcterms:extent>16 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-0MTXXNR4"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2003</dcterms:issued><dc:creator>Rotger, Margalida</dc:creator><dc:creator>Tomič, Viktorija</dc:creator><dc:creator>Trampuž, Andrej</dc:creator><dc:format xml:lang="sl">številka:10</dc:format><dc:format xml:lang="sl">letnik:72</dc:format><dc:format xml:lang="sl">str. 557-559</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:17018585</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-0MTXXNR4</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">antibiotic</dc:subject><dc:subject xml:lang="sl">antibiotiki</dc:subject><dc:subject xml:lang="en">bacteria</dc:subject><dc:subject xml:lang="sl">bakterije</dc:subject><dc:subject xml:lang="en">Drug Effects</dc:subject><dc:subject xml:lang="en">Drug Resistance, Microbial</dc:subject><dc:subject xml:lang="sl">infekcije</dc:subject><dc:subject xml:lang="en">Methicillin Resistance</dc:subject><dc:subject xml:lang="sl">Meticilinska rezistenca</dc:subject><dc:subject xml:lang="sl">Mupirocin</dc:subject><dc:subject xml:lang="sl">nos</dc:subject><dc:subject xml:lang="sl">odpornost</dc:subject><dc:subject xml:lang="sl">stafilokoki</dc:subject><dc:subject xml:lang="en">Staphylococcus Aureus</dc:subject><dc:subject xml:lang="sl">Zdravilo, rezistenca mikrobna</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">In vitro activity and emergence of resistance to mupirocin in Staphylococcus aureus| In vitro aktivnost in razvoj odpornosti proti mupirocinu pri bakteriji Staphylococcus aureus|</dc:title><dc:description xml:lang="sl">Background. Nasal carriage of Staphylococcus aureus is an important risk factor for later infection with the same strain. Topical mupirocin is used forS. aureus nasal decolonization. However, due to increasing mupirocin misuseresistance may develop rapidly. We determined the in vitro activity of mupirocin and compared the emergence of resistance among30 methicillin-susceptible S. aureus (MSSA) isolates and 30 methicillin-resistantS. aureus (MRSA) isolates. Methods. Minimal inhibitory concentrations (MICs) were determined according to the National Committee for Clinical Laboratory Standards (NCCLS). Emergence of resistance studies were performed by incubating the isolates with increasing concentrations of mupirocin (0.125 to 16 micro g/ml) over 8 days in Mueller-Hinton broth (MHB). Isolates were screened for resistance using Mueller-Hinton agar plates with 4 micro g/ml of mupirocin. Results. MICs were determined for all recovered isolates. Before mupirocin exposure, MSSA and MRSA MIC90 (range) in micro g/mlwere 0.25 (0.06-4) and 0.25 (0.06-0.5). After one day of mupirocin exposure, all recovered isolates demonstrated decreased susceptibility to mupirocin (MSSA MIC90 64 micro g/ml and MRSA MIC90 32 micro g/ml). On subsequent days, no further significant changes in the mupirocin MIC90 was detected. Conclusions. The in vitro study suggests that mupirocin resistance emerges easily and early after exposure to low antimicrobial concentrations. Therefore, mupirocin should be used prudently and should always be combined with other decolonization interventions such as gargling and skin wash with chlohexidine</dc:description><dc:description xml:lang="sl">Izhodišča. Nosilstvo Staphylococcus aureus v nosu predstavlja pomemben dejavnik tveganja za kasnejšo okužbo z istim sevom. Topični mupirocin se uspešno uporablja za dekolonizacijo nosu v primeru nosilstva bakterije S. aureus. Vse večja uporaba in predvsem zloraba mupirocina je lahko povezana z razvojem odpornosti bakterije S. aureus na ta antibiotik. V raziskavi smo določili in vitro aktivnost rriupirocina inprimerjali razvoj odpornosti med 30izolati za meticilin občutjivega S. aureus (MSSA90 in 30 izolati proti meticilinu odpornega S. aureus (MRSA). Metode. Minimalne inhibitorne koncentracije (MIK90 smo določili po priporočilih National Committee for Clinical laboratory Standards (NCCLS). Sposobnost razvoja odpornosti stafilokokov smo določili z inkubacijo izolatov v gojišču Mueller-Hinton z naraščajočo koncentracijo mupirocina (0,125 do 16 mikro g/ml) v času 8 dni. Namupirocin odporne izolate S. aureus smo osamili s pomočjo presejalnega gojišča Mueller-Hinton z vsebnostjo mupirocina v koncentraciji 4 mikro g/ml. Rezultati. MIK smo določili za vse izolate, ki so porasli na presejalnem gojišču. Pred izpostavljenostjo mupirocinu je MIK90 (razpon) v mikro g/ml za MSSA in MRSA znašal 0,25 (0,064) in 0,25 (0,06-0,5). Po enem dnevu izpostavljenosti mupirocinu so vsi izolati kazali zmanjšano občutljivost za mupirocin (MSSA MIK90 64 mikro g/ml in MRSA MIK90 32 mikro g/ml). Pri nadaljnji inkubaciji z naraščajočo koncentracijo mupirocina v naslednjih dneh nismo več opazili značilne spremembe MIK90 mupirocina. Zaključki. Naša raziskava in vitro nakazuje, da se lahko odpornost proti mupirocinu razvije zlahka in zgodaj po izpostavljenosti nizkim koncentracijam tega antibiotika. Zato je nujno, da mupirocin uporabljamo preudarno in vedno v povezavi z drugimi dekolonizacijskimi ukrepi, kot sta grgranje in umivanje kože s kloheksidinom</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-0MTXXNR4"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-0MTXXNR4" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-0MTXXNR4/88ea85cc-bc5c-49a4-9afc-6358594e95e2/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-0MTXXNR4/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-0MTXXNR4" /></ore:Aggregation></rdf:RDF>